Date published: 2026-7-5

1-800-457-3801

SCBT Portrait Logo
Seach Input

Flt-4 Double Nickase Plasmid (h): sc-400684-NIC

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • Flt-4 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
  • Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
  • One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
  • Flt-4 Double Nickase Plasmid (h) and Flt-4 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting FLT4. One or both designs may be available
  • Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Flt-4 Antibody (E-3): sc-514825
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    Flt-4 Double Nickase Plasmid (h)

    sc-400684-NIC
    20 µg
    $410.00

    Flt-4 Double Nickase Plasmid (h2)

    sc-400684-NIC-2
    20 µg
    $410.00

    FLT4 encodes Flt-4 (VEGFR-3), a receptor tyrosine kinase predominantly expressed in lymphatic endothelial cells that mediates signaling downstream of VEGFC and VEGFD. Ligand-induced receptor dimerization and autophosphorylation activates PI3K–AKT, MAPK/ERK, and PLCγ-dependent pathways to regulate lymphangiogenesis, endothelial survival, migration, and vascular remodeling. Dysregulated FLT4 signaling and altered lymphatic vessel development are linked to inherited lymphatic disorders and contribute to pathological lymphatic remodeling and tumor-associated lymphangiogenesis. As a pathway node integrating growth factor cues with endothelial transcriptional programs, FLT4 is widely studied in vascular biology, inflammation-associated tissue remodeling, and microenvironmental regulation of metastasis.

    Flt-4 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the FLT4 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within FLT4. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt FLT4 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.

    To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of FLT4-disrupted clones.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.